Nexsen Limited (ASX:NXN) announced on 25 September 2026 that it has entered a non-binding term sheet with FlashDx Shenzhen Inc. to form a 50:50 joint venture. Nexsen, an emerging leader in rapid point-of-care diagnostics, develops a growing portfolio for serious conditions where delays in diagnosis affect patient outcomes and limit clinician decisions. The proposed JV aims to develop and commercialise an enhanced molecular Group B Streptococcus (GBS) diagnostic test, building upon FlashDx’s existing CE-marked product to accelerate Nexsen’s commercialisation and establish manufacturing capabilities.
This strategic partnership is set to bring forward Nexsen’s commercial market entry across the Asia-Pacific region, with initial focus on Hong Kong and India. Nexsen will lead and fund the critical US Food and Drug Administration (FDA) 510(k) clearance and European Union In Vitro Diagnostic Medical Devices Regulation (CE-IVDR) conformity pathways, supported by FlashDx. The enhanced JV product targets hospital and intrapartum testing, expanding Nexsen’s GBS offering into a distinct molecular market that complements its existing StrepSure rapid lateral-flow program for antenatal screening. This broadens Nexsen’s overall GBS market opportunity, addressing the substantial need across ~132 million global births annually.
The joint venture leverages FlashDx’s established molecular technology and manufacturing capability, while Nexsen contributes a sample-preparation enhancement designed to improve detection at low bacterial levels. This provides a more advanced starting point than developing a molecular system from scratch, shortening the pathway to regulatory expansion. The non-binding term sheet specifies FlashDx will exclusively manufacture the GBS test for the JV, with Nexsen funding regulatory approvals and both parties participating equally in profits. The companies will now proceed to finalise definitive agreements and commence planning for commercial market entry and the US regulatory program.
